Unprecedented Progress Toward Affordable Drugs

In a historic step toward lowering the cost of prescription drugs for millions of Americans, President Donald J. Trump announced a new agreement with AstraZeneca that will allow all Medicaid programs across the United States to purchase the pharmaceutical company’s drugs at “most-favored-nation” (MFN) pricing—the lowest prices offered to any developed country. This deal marks the second such arrangement secured by the administration in recent months, following a similar agreement with Pfizer in September 2025.

Tackling a Broken System

The United States stands as the largest pharmaceutical market in the world, yet it has long endured the highest prescription drug prices among advanced economies. According to a 2023 RAND Corporation study, Americans pay an average of 2.56 times more for brand-name drugs than citizens of 32 other developed nations, even after adjusting for discounts and rebates. The new deal challenges a status quo that has seen U.S. consumers effectively subsidizing lower prices abroad—American patients bear the brunt of innovation costs, while foreign countries maintain strict price controls, securing lower rates for the same medicines.

Key Provisions of the AstraZeneca Agreement

• Medicaid Savings: All state Medicaid programs will now be able to purchase AstraZeneca products at the MFN price, a move projected to save American taxpayers hundreds of millions of dollars annually.
• Direct Discounts for Patients: American patients purchasing medicines directly will have access to drastic discounts, including major inhaler medications like BEVESPI AEROSPHERE, BREZTRI AEROSPHERE, and AIRSUPRA—saving patients up to 98% off prior deal prices.
• Global Revenue Reallocation: AstraZeneca will repatriate increased foreign revenues, gained from higher international pricing, to benefit American patients as a result of U.S. trade policy leverage.
• Future Innovation Pricing: All new, innovative medicines AstraZeneca brings to the market must be offered at the MFN price, preventing ongoing and future price disparities.

Impact on American Health and Economy

Over 9 million American patients reliant on AstraZeneca medications—and an estimated total of 25 million asthma sufferers and 16 million COPD patients nationwide—stand to benefit. Chronic obstructive pulmonary disease and asthma are among the top causes of disability and death in the U.S., and the price drop on critical inhalers is especially timely as out-of-pocket prescription expenses have climbed steadily, with some therapies previously costing upwards of $300–$400 monthly for uninsured patients.

The Centers for Medicare & Medicaid Services (CMS) estimates that prescription drugs account for nearly 10% of total U.S. personal healthcare spending, exceeding $410 billion in 2023. MFN pricing is expected to reduce that share, especially for Medicaid, which covers nearly 80 million low-income and vulnerable Americans.

Major Commitment to U.S. Jobs and Supply Chains

Alongside pricing reforms, AstraZeneca has pledged to invest $50 billion in U.S. manufacturing, research, and development by 2030. Central to this plan is a state-of-the-art facility in Charlottesville, Virginia, set to manufacture advanced pharmaceutical ingredients and support new drug development, particularly in chronic disease and cancer therapies. The project will create 3,600 highly skilled jobs and fortify the domestic supply chain—a crucial priority underscored by recent global medicine shortages and ongoing pandemic recovery efforts.

This investment follows the broader industry trend of reshoring pharmaceutical production, with U.S. and European Union policy initiatives encouraging local manufacturing to reduce reliance on global supply chains that have proven vulnerable in recent years.

Putting an End to Global Free-Riding

The Trump administration’s approach directly targets what it calls “global freeloading”—the practice of foreign governments negotiating much lower drug prices from U.S.-based pharmaceutical giants while benefiting from American-funded innovation. Statistics underline the problem: The U.S. accounts for less than 5% of global population but more than 75% of global pharmaceutical profits, with much of that money coming from American consumers and federal healthcare programs.

By enforcing MFN pricing, the administration seeks to deploy U.S. market power to rebalance pharmaceutical revenues and ensure the benefits of domestic investment and innovation reach American patients first, not just overseas health systems.

Trump Administration’s Broader Drug Pricing Reform Agenda

The AstraZeneca agreement builds on a series of aggressive policy moves intended to pressure both drug manufacturers and foreign governments. In May 2025, President Trump signed an Executive Order directing federal agencies to pursue MFN pricing on prescription drugs and, in subsequent months, issued formal directives to leading pharmaceutical firms to align U.S. patient costs with international benchmarks. The administration views the AstraZeneca and Pfizer deals as template agreements for future negotiations with other drugmakers.

While some industry advocates warn that MFN pricing may reduce pharmaceutical company incentives to develop new drugs, the administration contends that fairer, more predictable pricing in the world’s largest pharmaceutical market will drive sustainable innovation and investment, benefiting both U.S. patients and broader global health.

Reactions and the Road Ahead

Healthcare advocates, policy analysts, and state governors have welcomed the announcement, noting the potential for immediate out-of-pocket savings and the reduced burden on Medicaid budgets. Critics, however, caution that implementation details and potential knock-on effects—including international price shifting and possible access restrictions—must be closely monitored.

The pharmaceutical sector, meanwhile, is watching to see whether other major companies will follow AstraZeneca’s lead, potentially signaling a long-term transformation in how Americans pay for medicines. As the administration prepares for further negotiations, Americans—and the world—will be closely observing the outcome of Trump’s “America First” pharmaceutical policy, its impact on patients, and its ripple effects in the global market.